Direkt zum Inhalt
Merck

Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry.

eLife (2019-08-02)
Valeria Ramaglia, Salma Sheikh-Mohamed, Karen Legg, Calvin Park, Olga L Rojas, Stephanie Zandee, Fred Fu, Olga Ornatsky, Eric C Swanson, David Pitt, Alexandre Prat, Trevor D McKee, Jennifer L Gommerman
ZUSAMMENFASSUNG

Multiple sclerosis (MS) is characterized by demyelinated and inflammatory lesions in the brain and spinal cord that are highly variable in terms of cellular content. Here, we used imaging mass cytometry (IMC) to enable the simultaneous imaging of 15+ proteins within staged MS lesions. To test the potential for IMC to discriminate between different types of lesions, we selected a case with severe rebound MS disease activity after natalizumab cessation. With post-acquisition analysis pipelines we were able to: (1) Discriminate demyelinating macrophages from the resident microglial pool; (2) Determine which types of lymphocytes reside closest to blood vessels; (3) Identify multiple subsets of T and B cells, and (4) Ascertain dynamics of T cell phenotypes vis-à-vis lesion type and location. We propose that IMC will enable a comprehensive analysis of single-cell phenotypes, their functional states and cell-cell interactions in relation to lesion morphometry and demyelinating activity in MS patients.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-TMEM119 in Kaninchen hergestellte Antikörper, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution